The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients.
Study Type
OBSERVATIONAL
Enrollment
60
Effect/Correlation of direct oral anticoagulants (DOAC) on CoaguChek point-of-care testing (POCT) result
DOAC concentrations determined by ultra-performance liquid chromatography-tandem mass spectrometry
Time frame: 24 hours
Diagnostic accuracy of the CoaguChek POCT to rule out or detect relevant DOAC levels
Time frame: 24h
Effect/Correlation of DOAC on prothrombin time (PT), activated thromboplastin time (aPTT), anti-Xa activity and Hemoclot assay
Time frame: 24h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.